and after continuous infusion of remifentanil or
alfentanil.J. Pharmacol. Exp. Ther. 274 : 34–39.
Bardolph EM, Taylor RH. 1997. Sailors, scurvy, science
and authority.J. Roy. Soc. Med. 90 : 238.
Berry DA. 1985. Interim analyses in clinical trials: clas-
sical vs. Bayesian approaches.Stat. Med. 4 : 521–526.
Berry DA. 1995. Decision analysis and Bayesian
methods in clinical trials.Cancer Treat. Res. 75 :
125–154.
Chaput de Saintonge DM, Vere DW. 1982. Measure-
ment in clinical trials.Br. J. Clin. Pharmacol. 13 :
775–783.
Ebbutt AF. 1984. Three-period crossover designs for
two treatments.Biometrics 40 : 219–224.
Ellenberg SS. 1989. Determining sample sizes for
clinical trials.Oncology 3 : 39–42.
Freedman LS, White SJ. 1976. On the use of Pocock
and Simon’s method for balancing treatment num-
bers over prognostic factors in the controlled clinical
trial.Biometrics 32 : 691–694.
Freiman JA, Chalmers TC, Smith H, Kuebler RR. 1978.
The importance of beta, the type II error and sample
size in the design and interpretation of the rando-
mized control trial. New Engl. J. Med. 299 :
690–694.
Frey WG. 1969. British naval intelligence and scurvy.
New Engl. J. Med. 281 : 1430–1433.
Gehan EA. 1979. Clinical trials in cancer research.
Environ. Health Perspect. 32 : 31–48.
Kallis P, Tooze JA, Talbot S, Cowans D, Bevan DH,
Treasure T. 1994. Pre-operative aspirin decreases
platelet aggregation and increases post-operative
blood loss: a prospective, randomized, placebo-
controlled, double-blind, clinical trial in 100 patients
with chronic stable angina.Eur. J. Cardiothorac.
Surg. 8 : 404–409.
Laska E, Meisner M, Kushner HB. 1983. Optimal
crossover designs in the presence of carryover
effects.Biometrics 39 : 1087–1091.
Lind J. 1753. A treatise of the scurvy. 8vo. Edinburgh.
Marsh BT. 1990. Informed consent.J. Roy. Soc. Med.
83 : 603–606.
Milledge J. 2004. First controlled clinical trial?Br. Med.
J. 329 : 891.
Pocock SJ. 1992. When to stop a clinical trial.Br. Med.
J. 305 : 235–240.
Pocock SJ, Geller NL. 1986. Interim analyses in ran-
domized clinical trials.Drug Inf. J. 20 : 263–269.
Pocock SJ, Simon R. 1975. Sequential treatment
assignment with balancing for prognostic factors in
the controlled clinical trial.Biometrics 31 : 103–115.
Spilker B. 1991.Guide to clinical trials. Raven Press:
New York; 1156 (ISBN 0-88167-767-1,passim).
Strazis KP, Fox AW. 1993. Malignant hyperthermia: review
of published cases.Anesth. Analg. 77 : 297–304.
Taves DR. 1974. Minimization: a new method of
assigning patients to treatment and control groups.
Clin. Pharmacol. Ther. 15 : 443–453.
Temple R. 1997. Public hearings on ‘Myotrophin’,
Peripheral and Central Nervous System Drugs Advi-
sory Committee, May 8, 1997 (Also inBiocentury:
the Bernstein Report, vol. 5 (no. 40), p. A2).
Thomas DP. 1997. Sailors, scurvy and science.J. Roy.
Soc. Med. 90 : 50–54.
Treasure T, MacRae KD. 1998. Minimisation: the
platinum standard for trials? Br. Med. J. 317 :
362–363.
Whitehead J. 1999. A unified theory for sequential
clinical trials.Stat. Med. 18 : 2271–2286.
Willan AR, O’Brien BJ, Cook DJ. 1997. Benefit-risk
ratios in the assessment of the clinical evidence of a
new therapy.Control Clin. Trial 18 : 121–130.REFERENCES 117